The Hyderabad-based firm posted a profit after tax of Rs 222.4 crore during July-September last year.
The company's total income from operations increased by 27.6 per cent to Rs 1,913.9 crore in the second quarter (Q2) of this fiscal compared to Rs 1,500.4 crore in the same period last fiscal, Aurobindo Pharma said in a statement.
"The integrated business in generic formulations is auguring well to drive the operating performance of the company. We are also investing in specific new, differentiated products offerings such as Oncology, Hormones, Peptides and OTC business which we believe will complement our business in the coming years," Aurobindo Pharma Ltd Managing Director N Govindarajan said.
Shares of Aurobindo Pharma closed at Rs 238.35 apiece, down 1.71 per cent on the BSE.